Evidence map›Paper›PMID 42648119›Full record

ArticleStem cell research2026

Generation of two iPSC lines from ALS patients harboring C9orf72 hexanucleotide repeat expansions.

Dide Wu, Ana Kojic, Jay P Ross, Dong Li, Parker Walther, Neelam Goyal, Jacinda Sampson, Joseph C Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dide WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ana KojicStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jay P RossDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dong LiStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Parker WaltherGreenstone Biosciences, Palo Alto, CA 94304, USA.
Neelam GoyalDepartment of Neurology & Neurological Sciences, Stanford Medicine, Palo Alto, CA 94304, USA.
Jacinda SampsonDepartment of Neurology & Neurological Sciences, Stanford Medicine, Palo Alto, CA 94304, USA.
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: joewu@stanford.edu.

Funding

Assessing Effects of Microgravity on Cardiovascular Aging with AI and 3D OrganoidsUG3TR005845 · NCATS · STANFORD UNIVERSITY · PI BEHESHTI, AFSHIN, WU, JOSEPH C. · 2025 to 2025
$3.2M
Advancing Personalized Cardiac Organoids - Converging In Vitro, In Chemico, and In Silico ModelsUM1TR006031 · NCATS · STANFORD UNIVERSITY · PI Afshin Beheshti, Sarah C Heilshorn · 2026 to 2026
$3.1M
Modeling Susceptibility to Radiation Therapy-induced Cardiotoxicity Using Cell Village iPSCsR01HL171102 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA, Joseph C. Wu · 2024 to 2026
$2.1M
AI-driven Drug Discovery Targeting Cardiac Fibrosis in Aging HeartUG3AG097135 · NIA · STANFORD UNIVERSITY · PI SAYED, NAZISH, WU, JOSEPH C. · 2025 to 2025
$900k
NCATS NIH HHS UG3 TR005845NCATS NIH HHS UM1 TR006031NHLBI NIH HHS R01 HL171102NIA NIH HHS UG3 AG097135
6 · The paper itself

Abstract

The GGGGCC hexanucleotide repeat expansion (HRE) within the C9orf72 gene constitutes the leading genetic driver of amyotrophic lateral sclerosis (ALS). This fatal neurodegenerative disorder is characterized by the systematic loss of both the upper and lower motor neurons across both the central and peripheral nervous systems. This work describes the successful reprogramming of two human induced pluripotent stem cell (iPSC) lines originating from two independent ALS patients, both of whom carry a C9orf72 HRE mutation. Validation of the two established iPSC lines confirmed the expression of pluripotency markers, normal karyotypes, and successful trilineage differentiation. Consequently, these lines provide a robust in vitro platform to model ALS and study C9orf72-mediated disease mechanisms.

Indexed as

Amyotrophic Lateral SclerosisC9orf72 ProteinDNA Repeat ExpansionInduced Pluripotent Stem CellsCell DifferentiationCell LineFemaleHumansC9orf72 ProteinC9orf72 protein, human

Identifiers

PMID42648119
PMCPMC13592274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.